Researchers publish new clinical data on NR supplement, marking the 18th clinical trial on ChromaDex’s Niagen ingredient. ChromaDex has announced …
Continue reading “ChromaDex clinical trial shows anti-inflammatory effects of NR supplement”
New clinical research in ataxia-telangiectasia patients finds nicotinamide riboside improved ataxia scores and increased antibody levels. LA-based ChromaDex has shared …
Continue reading “ChromaDex nicotinamide riboside clinical trial results”
H&H Group expands Swisse healthy aging product line into growing NAD+ space with Niagen from ChromaDex. Los Angeles-based ChromaDex has announced …
Continue reading “ChromaDex and H&H announce Niagen supply agreement”
We dive into ChromaDex: the company behind the successful nicotinamide riboside supplement Tru Niagen®. Over the coming weeks, we will …
Continue reading “Longevity supplements report: ChromaDex profile”
LA-based company ChromaDex announces that it has entered into a securities purchase agreement for the sale of $25m of its …
Continue reading “Leading NAD+ company ChromaDex announces $25m raise”
ChromaDex CEO Rob Fried on regulatory approval, scaling-up and going global. LA-based ChromaDex is a global bioscience company whose ethos …
Continue reading “Exclusive: ChromaDex’s CEO on Longevity commercialisation”
Phase 2 study finds addition of a nutritional protocol into Covid-19 care pathway reduces recovery time to 6.6 days from …
Continue reading “ChromaDex releases results for NR study in C19 patients”
Defining longevity isn’t straightforward; to get there we must negotiate its determinants, drivers and diseases. If you ask someone what …
Targeting immune health – Tru Niagen Immune supplement uses NAD+ boost for the optimal maintenance and function of aging cells. …
